United Therapeutics says Sandoz lawsuit is meritless

United Therapeutics Corp (Nasdaq: UTHR) was named as a defendant, along with Smiths Medical ASD, in a lawsuit filed in federal court by Sandoz and RareGen, on April 16, 2019.

The lawsuit alleges that United Therapeutics engaged in anticompetitive conduct in connection with plaintiffs' efforts to launch their generic version of Remodulin (treprostinil) Injection.

United Therapeutics responded, saying: "We are disappointed by these meritless claims against us and expect to ultimately prevail. United Therapeutics was founded with the goal of serving patients with pulmonary arterial hypertension (PAH), and that remains our focus today. In 2015, Smiths Medical publicly announced that it was discontinuing the CADD-MS 3 system, which is used by many patients to deliver Remodulin, a continuously infused form of treprostinil manufactured by United Therapeutics. In response, we made a significant investment under an agreement with Smiths Medical that ensured the CADD-MS 3 system would continue to be available to deliver Remodulin for a period of time. Absent United Therapeutics taking this action, thousands of very sick PAH patients may not have been able to access necessary therapy. Meanwhile, we doubled-down on our efforts to innovate and develop new and improved systems to deliver this therapy.”